Literature DB >> 16759825

Stability of valacyclovir: implications for its oral bioavailability.

Gladys E Granero1, Gordon L Amidon.   

Abstract

The absolute bioavailability of the prodrug valacyclovir, the l-valyl ester of acyclovir, after oral administration is approximately 54.5%. Since premature hydrolysis of this prodrug in the intestinal lumen may be a possible reason for its incomplete bioavailability and the chemical and enzymatic stability of the valacyclovir has been investigated. Release rates were investigated in both phosphate buffers with varying pH as well as in human and dog gastrointestinal fluids. The stability of the prodrug was found to be dependent on pH. This prodrug is chemically stable along the acidic pH side (under 4), while the prodrug degrades in alkaline medium through a base-catalyzed pseudo-first-order kinetics. The degradation of the prodrug valacyclovir progressed faster in intestinal fluid than in phosphate buffer at the same pH. There was no appreciable release of valacyclovir neither in the human and dog stomach contents nor in phosphate buffers at pHs fewer than 4, although its degradation was fastest in the human and dog stomach contents. In light of this result, we can conclude that the degradation of the valacyclovir in the upper intestinal lumen is probably one of the causes of its poor bioavailability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759825     DOI: 10.1016/j.ijpharm.2006.01.050

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  20 in total

1.  In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose Escalation.

Authors:  Bei Yang; David E Smith
Journal:  Pharm Res       Date:  2017-08-02       Impact factor: 4.200

2.  Disposition kinetics of a dipeptide ester prodrug of acyclovir and its metabolites following intravenous and oral administrations in rat.

Authors:  Ravi S Talluri; Ripal Gaudana; Sudharshan Hariharan; Ritesh Jain; Ashim K Mitra
Journal:  Clin Res Regul Aff       Date:  2009-01-01

3.  Comparison of acyclovir and famciclovir for the treatment of Bell's palsy.

Authors:  Ho Joong Kim; Sang Hoon Kim; Junyang Jung; Sung Su Kim; Jae Yong Byun; Moon Suh Park; Seung Geun Yeo
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-12       Impact factor: 2.503

Review 4.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 5.  Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.

Authors:  Ruanne V Barnabas; Connie Celum
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

6.  Formulation development, optimization, and evaluation of sustained release tablet of valacyclovir hydrochloride by combined approach of floating and swelling for better gastric retention.

Authors:  Pratik Upadhyay; Kunal Nayak; Kaushika Patel; Jaymin Patel; Shreeraj Shah; Jayant Deshpande
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

7.  [Acute retinal necrosis from the virologist's perspective].

Authors:  P Rautenberg; L Grancicova; J Hillenkamp; B Nölle; J B Roider; H Fickenscher
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

Review 8.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

9.  Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.

Authors:  Sherifa Hasabelnaby; Ayman Goudah; Hitesh K Agarwal; Mosaad S M abd Alla; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2012-07-27       Impact factor: 6.514

10.  Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens.

Authors:  S Abdalla; C Briand; M Oualha; M Bendavid; A Béranger; S Benaboud; J-M Tréluyer; Y Zheng; C Capito; Z Demir; F Foissac; S Winter; I Gana; S Boujaafar; N Bouazza; D Hirt
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.